Maxwell Biosciences

Many viruses, bacteria and fungi are currently impossible to treat, especially when many of the bugs infect a patient all at once (called a polymicrobial infection). These pathogens drive some of the largest unmet medical needs like asthma, cystic fibrosis, post viral syndromes like Epstein Barr, Long COVID, fungal brain infections, dementias, deadly hospital acquired fungal and bacterial illness, and chronic sinus infections which are suffered by 12% of the population. Maxwell has selected a nasal spray application of MXB-22,510 to target chronic sinus infections are the first application of the biomimetic technology and has received highly encouraging written feedback from the FDA.

• The R&D program is backed by over $40M in government grants, awarded mostly to independent investigators at Stanford, NYU, Japanese CDC, Texas A&M, University of Texas, Baylor College of Medicine and others
• Backed by over $14M in venture stage investment from VCs & family offices
• Encouraging Pre-Investigational New Drug (Pre-IND) written response from FDA
• The FDA's Qualified Infectious Disease Program awards FDA Fast Track and an extra 5 years to the standard 7 year exclusivity period, for a total 12 year legal commercialization monopoly
• MXB-22,510: Selected as lead drug candidate due to its outstanding safety data, and broad spectrum efficacy against all tested bacteria (60+), all tested fungi (Candida auris, Candida albicans, mucor, and many others) and ability to destroy biofilms and bacterial persister cells (world first)
• MXB-22,510: Highly encouraging animal study data in three different animals: effective and non-toxic
• MXB-22,510: Highly encouraging human lung tissue data: effective and non-toxic
• MXB-22,510: Tested against all pathogens associated with chronic sinusitis and shows broad spectrum efficacy against all of them
• MXB-22,510: Does not create drug resistance as tested in bacteria after 30 passages, Pseudomonas aeruginosa (as tested by Prof Gill Diamond, University of Louisville School of Dentistry)
• MXB-22,510: Highly effective in immunocompromised mouse model of deadly fungal sinus infection (as tested by Dr David Corry at Baylor College of Medicine)

• 
  Maxwell Biosciences' Claromers Destroy Epstein-Barr

  BioSpace · May 19, 2026

• 
  Maxwell Biosciences: $20 Million Raised For Immune-Inspired Small Molecules

  Pulse 2.0 · Aug 11, 2025

  Maxwell Biosciences, a global health technology firm, has secured $20 million in funding to support FDA clinical trials and AI-based research.

• 
  Maxwell Biosciences Announces Closing of $20M Financing Round

  BioSpace · Aug 7, 2025

  Investment accelerates Maxwell's path toward FDA trials and global market readiness

• 
  Maxwell Biosciences Announces Closing of $20M Financing Round

  Yahoo Finance

  Investment accelerates Maxwell's path toward FDA trials and global market readiness Austin, Texas--(Newsfile Corp. - August 7, 2025) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™, today announced the closing of its $20 million financing round. The funds will support Maxwell's upcoming FDA clinical trials and advance AI-driven R&D. The funds will also expand commercialization in multiple other industries in